KOD
Kodiak Sciences Inc.
Late-stage retina biotech riding a multi-hundred-percent run-up into a dense 2026–2027 catalyst cluster (tarcocimab, KSI-501 and KSI-101). Chart from Finviz, always double-check the latest quote and news.

Deep dive on Ocular Therapeutix: from DEXTENZA to the late-stage AXPAXLI retina franchise, with SOL-1 topline data in wet AMD coming in late February 2026 and a balance sheet funded into 2028.

First-in-human data for the nPulse™ Cardiac Catheter Ablation System show high pulmonary vein isolation durability and low SAE rate in atrial fibrillation – but this is still a pre-commercial, single-platform story.

Gene therapy for ultra-rare immunodeficiency (LAD-I), a hard reset after last year’s CRL and the Danon shock, and a March 28, 2026 PDUFA that could flip sentiment in a name now trading near multi-year lows. This is a classic “platform vs. execution” test in gene therapy – with an additional potential upside lever in the form of a Rare Pediatric Disease Priority Review Voucher (PRV) if approval comes through.

Alvotech is not a typical development-stage biotech: it is a vertically integrated biosimilar platform that already generates hundreds of millions of dollars in revenue from launched products like AVT02 (adalimumab) and AVT04 (ustekinumab), while also running a crowded late-stage pipeline. The stock sits in that awkward middle ground between “early growth” and “heavy balance sheet”, with over 1B$ of debt but also positive adjusted EBITDA and operating profit in the latest 9-month period.

Quick take: RenovoRx brings fresh clinical data on its TAMP™ therapy platform to SIO 2026 (February 6). The event is not a registrational readout, but it is a real-world test of how much the market still cares about this targeted intra-arterial delivery story as the company starts to generate device revenues.

Definium Therapeutics (DFTX) is not a mature commercial pharma story; it is a clinical‑stage CNS and mental health company whose equity behaves like a classic high‑beta biotech: the tape is dominated by expectations around clinical data, regulatory interactions, and the company’s ability to fund its programs through to value‑defining milestones.

On February 4, 2026, Oncolytics announced that the FDA granted Fast Track designation to pelareorep combined with bevacizumab and FOLFIRI for adults with KRAS-mutant, microsatellite-stable metastatic colorectal cancer (MSS mCRC) in the second-line setting, after progression on a first-line oxaliplatin-based regimen. The designation is based on clinical signals from the REO 022 study and prior pelareorep experience across GI tumors and breast cance